Phase III Endpoint Setback For Takeda's Maribavir in 1L HSCT Setting
But Safety, Durable Response Benefits Seen
Executive Summary
Oral CMV drug did not meet primary non-inferiority endpoint in a comparative Phase III trial as a first-line therapy in stem cell transplant recipients, but demonstrated clinically meaningful and durable viremia clearance. Japanese firm discussing potential ways forward with regulators and impact on planned submission timelines currently unclear.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.